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Abstract
Background: Research indicates that low omega-3 polyunsaturated fatty acid (n-3 PUFA) may be associated with
decreased cognitive function. This study examined the association between n-3 PUFA status and cognitive function
in young Australian women.
Methods: This was a secondary outcome analysis of a cross-sectional study that recruited 300 healthy women (18–
35 y) of normal weight (NW: BMI 18.5–24.9 kg/m2) or obese weight (OB: BMI ≥30.0 kg/m2). Participants completed a
computer-based cognition testing battery (IntegNeuro™) evaluating the domains of impulsivity, attention,
information processing, memory and executive function. The Omega-3 Index (O3I) was used to determine n-3
PUFA status (percentage of EPA (20:5n-3) plus DHA (22:6n3) in the red cell membrane) and the participants were
divided into O3I tertile groups: T1 < 5.47%, T2 = 5.47–6.75%, T3 > 6.75%. Potential confounding factors of BMI,
inflammatory status (C-reactive Protein), physical activity (total MET-min/wk), alpha1-acid glycoprotein, serum ferritin
and hemoglobin, were assessed. Data reported as z-scores (mean ± SD), analyses via ANOVA and ANCOVA.
Results: Two hundred ninety-nine women (26.9 ± 5.4 y) completed the study (O3I data, n = 288). The ANOVA
showed no overall group differences but a significant group × cognition domain interaction (p < 0.01). Post hoc
tests showed that participants in the low O3I tertile group scored significantly lower on attention than the middle
group (p = 0.01; ES = 0.45 [0.15–0.74]), while the difference with the high group was borderline significant (p = 0.052;
ES = 0.38 [0.09–0.68]). After confounder adjustments, the low group had lower attention scores than both the
middle (p = 0.01) and high (p = 0.048) groups. These findings were supported by univariate analyses which found
significant group differences for the attention domain only (p = 0.004).
Conclusions: Cognitive function in the attention domain was lower in women with lower O3I, but still within normal
range. This reduced but normal level of cognition potentially provides a lower baseline from which cognition would
decline with age. Further investigation of individuals with low n-3 PUFA status is warranted.
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Background/objectives
Research on n-3 PUFA includes its potential role in
optimizing brain health and cognitive function [1–5].
Evidence also indicates that maintaining adequate body
levels of n-3 PUFA is important for optimizing health
across the lifespan [1–5]. While prevalence rates for
low n-3 PUFA status is lacking in Australia, studies in
Australian women highlight suboptimal intakes of n-3
PUFA, [6, 7] and results from the Australian Health
Survey [8] indicate young women are not meeting the
suggested dietary target (SDT) for chronic disease pre-
vention, [9] with mean intake falling at 41% of the SDT
[8]. Although beneficial associations between n-3 PUFA
status and cognitive performance have been reported,
the evidence is equivocal, with systematic reviews and
meta-analyses indicating no significant effect of n-3
PUFA supplementation on cognitive performance in
adults [2–5, 10].
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One factor that may reduce the capacity to observe
significant effects or associations is the use of plasma
n-3 PUFA assessment. The Omega-3 Index (O3I) is a
measure of erythrocyte eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA) and is known to be a
more accurate measure of n-3 PUFA status than serum
or plasma because it is indicative of omega-3 exposure
over the previous 3 months (reflecting the life cycle of
erythrocytes), rather than recent dietary intake [11].
Another factor is the influence of confounding variables
on cognitive function. Obesity and its associated co-
morbidities, including metabolic disease and systemic
inflammation, are particularly relevant as there is in-
creasing evidence for their association with cognitive
decline [12–19]. Physical inactivity, which is often
strongly associated with obesity, has also been linked
with cognitive decline or reduced cognitive perform-
ance [20–24]. Iron status also may impact cognitive
function [25, 26]. The impact of these confounding
variables should be considered when examining the
relationships between n-3 PUFA status and cognitive
function, but unfortunately, studies examining these
relationships rarely measure or adjust for these.
Given evidence of sub-optimal n-3 PUFA intake re-
ported in Australian women, [6, 7] the aim of this study
was to examine in young women the relationship be-
tween cognitive function and n-3 PUFA status measured
by the O3I. As obesity and physical inactivity currently
are increasing in this population group, [27–29] the
study also examined the potential confounding effects of
these factors (and additionally, of obesity-related sys-
temic inflammation) on cognitive function. The impact
of iron status was also examined because of recent
evidence for its influence on attention [25].
Subjects/methods
Study design and participants
As reported elsewhere (Cook et al., 2017), [25] this
cross-sectional study (Food, Mood & Mind) was de-
signed with the primary aim of assessing the iron status
and cognitive function in young (18–35 y) normal
weight (NW) (body mass index (BMI): 18.5–24.9 kg/m2)
and obese weight (OB) (BMI: ≥30.0 kg/m2) women. A
secondary aim was to assess the association between n-3
PUFA status (measured by O3I) and cognitive function
and this secondary outcome analysis is reported here.
Obesity, physical activity levels, systemic inflammation,
alpha1-acid glycoprotein and iron status were evaluated
as potential confounding factors. Participants were re-
cruited from both metropolitan (Sydney) and rural
(Bathurst) areas of Australia. Sample size was calculated
with respect to the primary outcome (iron and cogni-
tion) and the recruitment target was 300 healthy women
[25]. The study was approved by the associated Human
Research Ethics Committees of the participating univer-
sities and local health district services (protocol numbers
X10–0259, HREC/10/RPAH/455 and 2014/050).
Inclusion and exclusion criteria
Participants were eligible if they were healthy and had a
BMI in the normal weight or obese category according
to the WHO guidelines (BMI 18.5–24.9 and ≥ 30.0 kg/
m2 respectively) [30]. Exclusions were significant med-
ical conditions; disorders or medications which may
compromise cognitive function, vision, hearing, or motor
coordination; smoking; alcohol consumption ≥50 g per
week; and current pregnancy or breastfeeding. Partici-
pants were required to be literate in English.
Data collection
Participants attended two separate appointments (at a
university laboratory or an obesity clinic within a major
university teaching hospital) approximately 1 week
apart. The first session involved informed consent,
anthropometric measurements (weight, height, waist
circumference), cognitive testing and a battery of ques-
tionnaires. All testing was conducted after breakfast
and prior to 1300 h. Participants were asked to refrain
from heavy exercise, alcohol and caffeine (and other
stimulants) on the morning of the cognition test and to
consume their usual breakfast to ensure that they were
not hungry during the testing session. Caffeine was ex-
cluded as it has been shown to reduce fatigue and help
increase attention. The second visit involved collection
of a fasting blood sample, thus avoiding the fasting state
for cognitive testing.
Cognition assessment
Cognitive function was assessed using a validated touch-
screen cognition testing platform, IntegNeuro™ (©Brain
Resource Company) [31]. Performance on a total of 14
tests is used to formulate z-scores across five cognitive
domains: attention, impulsivity, information processing,
memory and executive function. Z-score normal range is
+ 1 to − 1 standard deviation and scores are adjusted for
age, sex and years of education. Positive scores reflect
better than average performance while negative scores
reflect lower than average performance. Outliers lower
than − 4 z-score were excluded from the analysis (< 4%,
n = 11); there were no outliers greater than + 4 z-score.
Blood collection and biochemical analysis
Biochemical analysis was performed by a National Asso-
ciation of Testing Authorities (NATA) Australia accre-
dited diagnostic laboratory. Inflammation was analyzed
via C-reactive Protein (CRP) using CRP Rate Nephelom-
etry on COBAS 8000 e602 and alpha-1 acid glycoprotein
(α1GP) using immunoturbidimetry on a Konelab 20XT
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Clinical Chemistry Analyzer (using reagent from Thermo
Fisher), with CRP > 5.0mg/L and/or α1GP > 1.0 g/L indi-
cative of raised levels of inflammation (CRP reference
range ≤ 5.0; α1GP reference range ≤ 1.0) [32, 33].
Hemoglobin (Hb) was measured via absorption spectro-
photometry and flow cytometry on the Abbot CELL-DYN
Sapphire System (Hb reference range 120-150 g/L). Iron
markers were analyzed via automated immunoassay on
the Roche COBAS 8000 e602 and the raw serum ferritin
(SF) values (reference range 20-300μg/L) were corrected
for inflammation as described previously [25].
The O3I analysis was conducted at a university la-
boratory using trans-esterification of the washed
erythrocyte fraction of blood followed by gas chroma-
tography using a fixed carbon-silica column 30 m ×
0.25 mm (DB-225) (J and W Scientific) [34]. The O3I
was used as a reliable indicator of overall n-3 PUFA
status and was calculated by addition of the percentage
of EPA (20:5n-3) and DHA (22:6n-3) in each erythro-
cyte sample as proportions of total erythrocyte mem-
brane fatty acids in each sample [11, 33–35].
Physical activity assessment
The short form of the International Physical Activity
Questionnaire (IPAQ) was used to assess overall level of
physical activity (PA) in Metabolic Equivalent of the
Task (MET)-minutes (min)/week (wk). The IPAQ allows
collation of comparable estimates of PA and has been
validated transnationally [36, 37].
Statistical analyses
In order to explore the relationship between n-3 PUFA
status measured by the O3I and cognitive function, the
participants were divided into O3I tertile groups (n = 96
per group). Initial one-way analyses of variance (ANO-
VAs) were conducted on demographic characteristics
and the potential confounders of BMI, CRP, PA, α1GP,
SF and Hb. The relationship between O3I and cognitive
function was then investigated using two-way (3 × 5)
ANOVAs with O3I tertiles as an independent groups
factor (T1, T2, T3) and the five z-scores (impulsivity, at-
tention, information processing, memory, executive
function) as a repeated measures factor. Tukey’s post
hoc tests were used in all cases to determine the precise
locus of any significant differences observed. Subse-
quently, the variables of BMI, CRP, PA, α1GP, SF and
Hb were added as covariates to the 3 × 5 ANOVA
models. Univariate analyses were also carried out within
each ANOVA and ANCOVA to examine group differ-
ences on the z-scores for each cognitive domain. Signifi-
cance for all analyses was set at p < 0.05. In the text and
tables, all results are reported as mean ± standard de-
viation (SD) and between-group differences as effect size
(ES) ± 95% confidence interval (CI). All statistical
analyses were carried out using Statistica software (v.12;
StatSoft Inc., Tulsa, OK, USA).
Results
The screening and recruitment of participants are sum-
marized in Fig. 1. Although 299 women completed the
study, blood samples could not be assayed in 11 cases,
hence the analysis was based on 288 participants.
The demographic characteristics of the tertile groups,
as well as their biochemical markers, are shown in
Table 1. Years of education varied significantly across
the groups (p = 0.02), the post hoc tests showing that
the lowest O3I tertile group had about 1 year less edu-
cation than the highest group (p = 0.02) while the
difference from the middle group was not significant
(p = 0.10). Of the five covariates, the O3I groups did
not differ significantly on PA, SF or Hb, but there were
significant group differences in BMI (and weight), CRP
and α1GP levels. Post hoc pairwise comparisons
showed that the lowest O3I group differed significantly
from the highest group on these three variables (p ≤
0.02) but differed significantly from the middle group
only on α1GP levels (p = 0.03). There were proportion-
ately more participants with normal weight in the high-
est tertile group and more participants with obesity in
the lowest tertile group (p < 0.0001).
The cognitive function of the three groups was
assessed across the five domains. The mean z-scores for
each domain across all O3I tertile groups were in the
normal range (Fig. 2). The ANOVA showed no signifi-
cant overall difference between the groups (p = 0.22) but
there was a significant interaction between groups and
cognitive domains (p < 0.01). Examination of the mean
values in Fig. 2 shows that the locus of this interaction
was the attention domain, with the lowest tertile group
having a lower score than the other two groups. Post
hoc tests on this interaction confirmed that the lowest
tertile group scored significantly lower on attention than
the middle group (p = 0.01; ES = 0.45 [0.15–0.74]), while
the difference with the highest group was borderline sig-
nificant (p = 0.052; ES = 0.38 [0.09–0.68]). The middle
and highest O3I groups had similar attention scores.
Univariate analyses on each domain across the three
groups confirmed a significant group effect only for
attention (p = 0.004).
Of the five covariates, only BMI and CRP showed
significant (weak) correlations with cognition domains,
specifically attention and memory (r = − 0.14 to − 0.22,
p ≤ 0.02). BMI and CRP were also found to be positively
correlated with each other (r = 0.67, p < 0.0001). Conse-
quently, only the analyses of covariance with these two
covariates had any effect relative to the unadjusted
model and so only they will be reported. Similar to the
unadjusted model, there were no significant overall
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group effects after adjusting individually for BMI (p =
0.28) and CRP (p = 0.23). The group × domain inter-
action was still significant for CRP (p = 0.013) but now
borderline for BMI (p = 0.053), the locus again being the
attention domain. Given these p values, post hoc tests
were carried out in both cases and showed that for BMI,
the lowest O3I group scored significantly lower on at-
tention than both the middle (p = 0.01) and highest (p =
0.047) O3I groups, while for CRP, the lowest group
scored significantly lower on attention than the middle
group (p = 0.01) and was borderline significant with the
highest group (p = 0.050). The middle and highest O3I
groups again had similar performance scores. The uni-
variate analyses on each domain across the three groups
again confirmed significant effects for attention only
(p ≤ 0.029).
When these two covariates were combined in one
ANCOVA model, the pattern of results mirrored that
found after adjusting for BMI alone (the lack of further
effect of CRP can be attributed to the degree of collin-
earity between these covariates). There was no signifi-
cant group effect (p = 0.27) and the group x domain
interaction was again borderline (p = 0.054). Given this p
value, post hoc pairwise comparisons were carried out
and again showed that the lowest O3I group had signifi-
cantly lower performance on attention than both the
middle (p = 0.01) and highest (p = 0.048) O3I groups.
The middle and highest O3I groups had similar atten-
tion scores. The univariate analyses were again signifi-
cant for the attention domain (p = 0.029).
In summary, no overall group effect was observed
with either the ANOVA or ANCOVA models but in
each case, post hoc tests on significant group x do-
main interactions revealed a pattern whereby the
lowest O3I tertile group scored significantly lower
than the middle and highest tertile groups in the
Fig. 1 Participant recruitment and study participation flow chart
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cognitive domain of attention, with the latter groups
showing similar scores. These findings were sup-
ported in each case by the univariate analyses, which
found significant group differences for the attention
domain (Fig. 2). When these ANOVA models were
repeated on quartile (n = 72) and quintile (n = 57)
O3I groups, a similar pattern of results was observed.
There were no overall group effects but there were
significant group × domain interactions (p < 0.02) on
which post hoc tests revealed that the lowest quartile
and quintile groups scored lowest in the domain of
attention. Again, significant group differences in the
Table 1 Demographics and biochemical markers (mean ± SD)
Total group
(n = 288)
Tertile 1 < 5.47 Tertile 2 = 5.47–6.75 Tertile 3 > 6.75 P-valuea
(n = 96) (n = 96) (n = 96)
Omega-3 Index (%) 6.3 ± 1.7 4.7 ± 0.8 6.1 ± 0.4 8.1 ± 1.5 < 0.0001
Age (y) 25.8 ± 5.1 25.3 ± 5.2 25.7 ± 5.2 26.2 ± 4.8 0.47
Education (y) 16.2 ± 2.2 15.7 ± 2.2 16.3 ± 2.1 16.6 ± 2.2 0.02
Weight (kg) 78.0 ± 22.9 85.6 ± 24.5 80.2 ± 22.7 68.0 ± 17.7 < 0.0001
BMI (kg/m2) 28.5 ± 8.4 31.6 ± 9.3 28.9 ± 8.2 25.1 ± 6.0 < 0.0001
Normal weight 18.5–24.9 150 34 48 68
< 0.0001
Obese weight≥ 30.0 138 62 47 28
CRP (mg/L) Normal Range: < 5 mg/L 3.3 ± 4.2 4.0 ± 4.7 3.6 ± 4.2 2.3 ± 3.3 0.01
α1GP (mg/L) Normal Range: < 1 g/L 0.74 ± 0.22 0.82 ± 0.21 0.75 ± 0.21 0.66 ± 0.22 < 0.0001
Physical Activity (MET-min/wk) 2634 ± 2144 2641 ± 2121 2542 ± 2251 2718 ± 2074 0.85
SF (corrected) ug/L Normal range 20–300 g/L 42.9 ± 31.8 37.6 ± 26.4 44.4 ± 38.9 46.7 ± 28.2 0.12
Hb (g/L) Normal Range: 120–150 g/L 134.4 ± 9.8 135.9 ± 10.2 133.9 ± 10.0 133.3 ± 9.1 0.17
aOne-way ANOVA on all variables except Chi-square test for weight category distributions. Abbreviations: O3I omega-3 index, BMI body mass index, CRP C-reactive
Protein, α1GP alpha1-acid glycoprotein, MET metabolic equivalent of task, min minute, wk. week, SF serum ferritin, Hb hemoglobin. Missing data: α1GP (n = 10),
Hb (n = 2)
Fig. 2 Omega-3 Index tertile groups (T1, T2, T3) versus cognitive performance in young women. Mean z-score ± SE (standard error); normal z-
score is + 1 to − 1. *p = 0.004 on univariate analysis
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attention domain were observed on univariate ana-
lyses (p < 0.01).
Discussion
This cross-sectional study examined the association of
O3I with cognitive function in young, healthy, normal
weight and obese women. While the cognitive per-
formance of the participants was within the normal
range, the study provides evidence for decreased per-
formance in the attention domain in women with a
lower Omega-3 Index. The major significant group dif-
ferences remained after adjustment for known con-
founders, with the post hoc tests still significant. Of
the five confounders, BMI appeared to be most
strongly linked to cognition. While a cut-off for n-3
PUFA intake for optimal brain health in young adults
cannot be suggested at this stage, the lowest O3I tertile
range (< 5.47%) may be sub-optimal for cognitive func-
tion. The reduced but normal level of cognition associ-
ated with lower n-3 PUFA potentially provides a lower
baseline from which cognition would continue to
decline with age.
There are a relatively small number of studies exam-
ining the effects of n-3 PUFA on cognitive function in
young adults, ranging from randomized controlled tri-
als to observational studies [1, 7, 38–45]. The majority
of studies include psychometric tests measuring atten-
tion, memory and information processing, with mem-
ory tests more heavily represented in the literature.
Overall, the evidence in healthy young adults suggests
that dietary supplementation with n-3 PUFA does not
enhance cognitive function, with only a handful of
studies showing clear significant benefits on memory
[40], information processing [44] and attention [43].
Importantly, none of the above-mentioned studies ad-
justed for confounders, which is a strength of our
study. There is evidence however that a threshold
effect of low n-3 PUFA on cognition may explain non-
significant findings [38, 46, 47]; hence the effects of n-
3 PUFA supplementation in healthy participants may
only be evident when cognitive performance is below
average at baseline, or when n-3 PUFA status falls
below a certain level (low or inadequate) [38]. Baseline
or inadequate O3I levels has also been investigated in
elderly cohorts, with O3I cut-off values suggested to
define targets for future dementia trials. A study in
dementia-free adults (70 years and over) reported an
optimal cut-off of 5.3% for predicting notable cognitive
decline and/or polyunsaturated fatty acid supplementa-
tion treatment response [48]. This cut-off is close to
that for the lowest O3I tertile group in the current
study (< 5.47%).
Several mechanisms of action have been proposed
to explain the relationship between n-3 PUFA and
cognitive function. First, PUFAs are known to facili-
tate effects on gene expression, especially in the cen-
tral nervous system [1, 50–52]. One genetic factor
that is attracting increasing attention is the Apolipo-
protein E (APOE) genotype, which has been linked to
Alzheimer’s disease. There is some evidence that this
gene variant is also linked to cognitive performance
in healthy young adults, but at present studies are
conflicting and there is no consensus in the literature
[49, 53, 54]. Secondly, it is known that n-3 PUFA has
an important role in maintaining membrane integrity
and fluidity, and neuronal functioning has been
shown to be influenced by n-3 PUFA through a de-
crease in inflammatory pathways [1, 55, 56]. In sup-
port of the published reports, [57] C-reactive protein,
an indicator of low-grade sustained inflammation, was
lowest in women with the higher O3I in the present
study, supporting a possible role of inflammation in
determination of the attention domain of cognitive
function.
Effects have also been found on dopaminergic
neurotransmission, in particular, the mesocortical
pathway has been implicated in attention, memory
and executive function [56, 58, 59]. If these dopamin-
ergic systems are altered via low n-3 PUFA, deficiency
in this nutrient may contribute to reduced cognitive
function. A recent study in diabetic rodents showed
that administration of low doses of n-3 PUFAs could
protect against neuronal damage in the hippocampus
in type 2 diabetes and was associated with improved
cognitive-behavioral performance and reduced inflam-
matory markers [55]. Furthermore, animal studies
have reported evidence that n-3 PUFA (more specific-
ally DHA) accumulates in areas of the brain involved
in attention and memory, including the cerebral cor-
tex and hippocampus [60, 61]. This observation is of
interest, given that the current study found evidence
of reduced cognitive function in the attention domain
with lower O3I, albeit with no evidence of an effect on
memory. There is limited information on the impact
of short-term versus chronic inadequacy of n-3 PUFA
or low O3I on cognition. However, in maternal and
infant studies, there is evidence that there are crucial
periods for adequate n-3 PUFA which may impact
neurocognitive development [1, 3–5].
A major strength of this study is the recruitment of a
large, healthy cohort, free of comorbidities. This study is
one of the first to comprehensively exclude and/or ad-
just for a broad range of confounding variables when
examining the influence of n-3 PUFA status on cognitive
function in young women. Additionally, the use of
erythrocyte n-3 PUFA (allowing for the calculation of
the Omega-3 Index) provided an accurate and validated
measure of longer-term n-3 PUFA status. Another major
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strength is the use of well-validated tools (IPAQ, Integ-
Neuro™) to assess outcome measures.
A limitation of this study is that it is not possible to
deduce causal effects due to the cross-sectional study de-
sign. Limitations more generally in the examination of
the effect of n-3 PUFA on cognitive function include use
of plasma or serum n-3 PUFA to classify status. The
long-term measure of erythrocyte n-3 PUFA may be
more precise but is less accessible. A major limitation in
the literature, particularly in the studies conducted in
young adults, is that confounder adjustment for factors
that may potentially influence cognition, including in-
flammation, obesity and physical activity, is rarely con-
ducted. Previous systematic reviews assessing the effect
of n-3 PUFA supplementation on cognitive function
have also cited large heterogeneity in supplement inter-
ventions (the type of supplement, EPA/DHA content,
duration of intervention, etc.) and variability in cognition
assessment, as major limitations in this field [3, 10, 42].
There is also currently no consensus regarding the clas-
sification of cognitive tests and domains [16] and this
lack may explain some of the discrepancies in results
between studies.
Conclusions
This study found reduced cognitive performance in the
attention domain in young women with lower overall n-
3 PUFA, although cognition scores were still within the
normal range. Thus, the clinical significance of these
findings warrants further investigation. Cognition testing
pre- and post-intervention to rectify low n-3 PUFA
status and assessment of genetic factors (particularly
APOE4 and dopamine receptor genes) may help to fur-
ther identify the relationship and mechanisms of action
between n-3 PUFA status and cognitive performance.
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